Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Bioxcel Therapeutics ( (BTAI) ) has provided an announcement.
On January 15, 2025, BioXcel Therapeutics increased its Board of Directors from seven to eight members by appointing Dr. Rajiv Patni as a Class II director. Dr. Patni brings extensive experience in global product development within the biopharmaceutical sector and is expected to contribute significant value to the company’s strategic direction.
More about Bioxcel Therapeutics
BioXcel Therapeutics, Inc. is a company operating in the biopharmaceutical industry, primarily focused on developing treatments across various therapeutic areas such as cardiology, diabetology, hepatology, neurology, and benign hematology.
YTD Price Performance: -11.28%
Average Trading Volume: 860,006
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $17.7M
For a thorough assessment of BTAI stock, go to TipRanks’ Stock Analysis page.
